SA
HALO icon

Strategic Advocates’s Halozyme HALO Stock Holding History

Strategic Advocates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.53K Buy
+101
New +$7.12K 0.03% 170

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Advocates's HALO Position: Q1 2026 in Review

Strategic Advocates opened a new position in Halozyme (HALO) in Q1 2026: 101 shares worth $6.53K. The stake represents 0.03% of the portfolio and ranks #170 among its holdings.

634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Strategic Advocates held 101 shares of Halozyme worth $6.53K as of Q1 2026.
  • Halozyme was a new Strategic Advocates position in Q1 2026.
  • Halozyme made up 0.03% of Strategic Advocates's portfolio in Q1 2026, its #170 holding.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.